Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment

T Fehm; D Felsenberg; M Krimmel; E Solomayer; D Wallwiener; P Hadjii

doi:10.1016/j.breast.2009.07.001

Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment

Breast. 2009 Aug;18(4):213-7. doi: 10.1016/j.breast.2009.07.001. Epub 2009 Aug 3.

Authors

T Fehm¹, D Felsenberg, M Krimmel, E Solomayer, D Wallwiener, P Hadjii

Affiliation

¹ University Women's Hospital Tübingen, Calwer Strasse 7, 72076 Tübingen, Germany. tanja.fehm@med.uni-tuebingen.de

PMID: 19651512
DOI: 10.1016/j.breast.2009.07.001

Abstract

Osteonecrosis of the jaw (ONJ) is a rare but severe disease which has been diagnosed in women with breast cancer on a bisphosphonate (BP) therapy. Thus, the German society of senology appointed a multidisciplinary task force to establish a consensus on the use of bisphosphonates in breast cancer patients with bone metastases, considering in particular the possible risk of ONJ. This report summarizes the results and recommendations for the prevention and treatment of ONJ in breast cancer patients receiving BP.

Publication types

Review

MeSH terms

Bone Neoplasms / drug therapy*
Bone Neoplasms / secondary
Breast Neoplasms / epidemiology
Breast Neoplasms / pathology*
Comorbidity
Dental Care
Diphosphonates / administration & dosage
Diphosphonates / adverse effects*
Diphosphonates / therapeutic use
Female
Humans
Jaw Diseases / chemically induced*
Jaw Diseases / epidemiology
Jaw Diseases / prevention & control
Osteonecrosis / chemically induced*
Osteonecrosis / epidemiology
Osteonecrosis / prevention & control
Osteoporosis / drug therapy
Osteoporosis / epidemiology
Risk Factors

Substances

Diphosphonates